154 related articles for article (PubMed ID: 19092106)
1. Memantine induces reversible neurologic impairment in patients with MS.
Villoslada P; Arrondo G; Sepulcre J; Alegre M; Artieda J
Neurology; 2009 May; 72(19):1630-3. PubMed ID: 19092106
[TBL] [Abstract][Full Text] [Related]
2. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study.
Schifitto G; Navia BA; Yiannoutsos CT; Marra CM; Chang L; Ernst T; Jarvik JG; Miller EN; Singer EJ; Ellis RJ; Kolson DL; Simpson D; Nath A; Berger J; Shriver SL; Millar LL; Colquhoun D; Lenkinski R; Gonzalez RG; Lipton SA; ; ;
AIDS; 2007 Sep; 21(14):1877-86. PubMed ID: 17721095
[TBL] [Abstract][Full Text] [Related]
3. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.
Peyro Saint Paul L; Creveuil C; Heinzlef O; De Seze J; Vermersch P; Castelnovo G; Cabre P; Debouverie M; Brochet B; Dupuy B; Lebiez P; Sartori É; Clavelou P; Brassat D; Lebrun-Frenay C; Daplaud D; Pelletier J; Coman I; Hautecoeur P; Tourbah A; Defer G
J Neurol Sci; 2016 Apr; 363():69-76. PubMed ID: 27000224
[TBL] [Abstract][Full Text] [Related]
5. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.
Aarsland D; Ballard C; Walker Z; Bostrom F; Alves G; Kossakowski K; Leroi I; Pozo-Rodriguez F; Minthon L; Londos E
Lancet Neurol; 2009 Jul; 8(7):613-8. PubMed ID: 19520613
[TBL] [Abstract][Full Text] [Related]
6. A randomized crossover study of bee sting therapy for multiple sclerosis.
Wesselius T; Heersema DJ; Mostert JP; Heerings M; Admiraal-Behloul F; Talebian A; van Buchem MA; De Keyser J
Neurology; 2005 Dec; 65(11):1764-8. PubMed ID: 16221950
[TBL] [Abstract][Full Text] [Related]
7. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
Pomara N; Ott BR; Peskind E; Resnick EM
Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
[TBL] [Abstract][Full Text] [Related]
8. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial.
Schwid SR; Goodman AD; Weinstein A; McDermott MP; Johnson KP;
J Neurol Sci; 2007 Apr; 255(1-2):57-63. PubMed ID: 17331542
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
Wilkinson D; Andersen HF
Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
[TBL] [Abstract][Full Text] [Related]
10. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study.
Aragona M; Onesti E; Tomassini V; Conte A; Gupta S; Gilio F; Pantano P; Pozzilli C; Inghilleri M
Clin Neuropharmacol; 2009; 32(1):41-7. PubMed ID: 18978501
[TBL] [Abstract][Full Text] [Related]
11. Tinnitus treatment with memantine.
Figueiredo RR; Langguth B; Mello de Oliveira P; Aparecida de Azevedo A
Otolaryngol Head Neck Surg; 2008 Apr; 138(4):492-6. PubMed ID: 18359360
[TBL] [Abstract][Full Text] [Related]
12. A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI).
Ferris S; Schneider L; Farmer M; Kay G; Crook T
Int J Geriatr Psychiatry; 2007 May; 22(5):448-55. PubMed ID: 17117395
[TBL] [Abstract][Full Text] [Related]
13. Understanding pseudo: the symptoms are real, the cause is unclear.
Green AJ
Neurology; 2009 May; 72(19):1626-7. PubMed ID: 19246422
[No Abstract] [Full Text] [Related]
14. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
[TBL] [Abstract][Full Text] [Related]
15. Cognitive training in MS: effects and relation to brain atrophy.
Hildebrandt H; Lanz M; Hahn HK; Hoffmann E; Schwarze B; Schwendemann G; Kraus JA
Restor Neurol Neurosci; 2007; 25(1):33-43. PubMed ID: 17473394
[TBL] [Abstract][Full Text] [Related]
16. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial of memantine as treatment for spasticity in multiple sclerosis.
Mehta LR; McDermott MP; Goodman AD; Schwid SR
Mult Scler; 2010 Feb; 16(2):248-51. PubMed ID: 20028712
[TBL] [Abstract][Full Text] [Related]
18. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
Patti F; Amato MP; Bastianello S; Caniatti L; Di Monte E; Ferrazza P; Goretti B; Gallo P; Morra VB; Lo Fermo S; Picconi O; Tola MR; Trojano M;
Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
[TBL] [Abstract][Full Text] [Related]
19. The association between cognitive impairment and quality of life in patients with early multiple sclerosis.
Glanz BI; Healy BC; Rintell DJ; Jaffin SK; Bakshi R; Weiner HL
J Neurol Sci; 2010 Mar; 290(1-2):75-9. PubMed ID: 19944429
[TBL] [Abstract][Full Text] [Related]
20. A 3-year longitudinal study of cognitive impairment in patients with primary progressive multiple sclerosis: speed matters.
Denney DR; Lynch SG; Parmenter BA
J Neurol Sci; 2008 Apr; 267(1-2):129-36. PubMed ID: 17976653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
